Archive


Category: Atrial Fibrillation

  • Apple adds medication tracking to iPhone and Apple Watch

    Owners of an iPhone or Apple Watch have a new health feature, an app called Medications, that will help them manage and track their use of medicines. The new tool works as a component of Apple’s Health app and will let users add drugs or other health products like vitamins and supplements to a personal […]

  • Geisinger & Tempus Create AI Model to Identify Structural Heart Disease

    What You Should Know: – Tempus, an $8B precision medicine company, announced a collaborative study with Geisinger focusing on artificial intelligence (AI) model that can accurately identify patients at increased risk of undiagnosed structural heart disease (SHD). The study addresses a critical diagnostic gap – SHD is a progressive disease that affects the valves, walls, chambers, and muscles of the […]

  • Fitbit Receives FDA Clearance for New PPG Algorithm to Identify AFib

    What You Should Know: – Fitbit announced it has received clearance from the FDA for its PPG (photoplethysmography) algorithm to identify atrial fibrillation (AFib), a condition that affects more than 33.5 million people globally.  – The algorithm will soon be available to users in the U.S. through Fitbit’s new Irregular Heart Rhythm Notifications feature on eligible heart-rate tracking devices. We can share the full list at feature availability. PPG AFib detection Benefits AFib […]

  • Google seeks FDA nod for passive AFib detection with Fitbit

    Tech giant Google has filed for FDA approval to use its Fitbit wearable to help detect atrial fibrillation (AFib), a common heart abnormality that raises the risk of heart attack, stroke and sudden death. Fitbit is already approved by the FDA to provide electrocardiogram (ECG) monitoring of heart rhythms, and in 2020 its Sense Smartwatch […]

  • Eko Unveils Newly Designed Heart Disease Detection App

    What You Should Know: – Eko, a digital health company advancing heart and lung disease detection, today announced the launch of its newly-redesigned Eko App, which will transform patient interactions into an opportunity to screen for cardiovascular disease. Heart disease is the leading cause of death in the U.S., and there has not been an […]

  • Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration

    Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage […]

  • Study shows Fitbit can detect AFib, but faces hurdles to clinical use

    The results, shared at AHA 2021, found that a third of adults who used an ECG patch after getting a heart rhythm notification from their Fitbit had atrial fibrillation. However, the study faced some challenges with adherence, as many patients who got a notification did not follow up.

  • AI could be used to guide drug therapy for heart failure

    UK researchers have used artificial intelligence (AI) to develop a way to identify patients with heart failure who would benefit from treatment with beta blockers, by interrogating data from nine landmark clinical trials. The study applied machine learning to trial data involving 15,659 patients who were being treated for heart failure with reduced ejection fraction […]

  • Real-world study suggest AI may improve atrial fibrillation screening

    An artificial intelligence algorithm already shown to be able to detect atrial fibrillation (AF) in clinical testing has also shown its worth in a real-world setting, according to its developers. The AI – developed by the Bristol Myers Squibb-Pfizer Alliance on cardiovascular disease – was developed using machine learning from a UK dataset of almost […]

  • Abbott Reports Head-to-Head Data for Amplatzer Amulet Against Boston Scientific’s Watchman Device to Treat Atrial Fibrillation #ESC2021

    Shots: The head-to-head Amulet IDE study compares Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with the Watchman device to treat patients with AFib at an increased risk of stroke The study demonstrated superiority for the 1EPs of LAA (98.9% vs 96.8%) and was non-inferior for the co-primary safety & effectiveness endpoints Abbott’s Amulet Occluder with […]

  • AliveCor seeks ban on import of Apple Watches

    The digital health company filed a complaint with the Federal Trade Commission last week, seeking a ban on the import of the Apple Watch. AliveCor cited copyright violations related to Apple’s ECG feature as the reason for seeking the ban. 

  • MedLumics raises €18 million for atrial fibrillation device

    MedLumics has raised another €18 million (around $22 million) to fund clinical trials of its optically-guided imaging system used to guide a surgical procedure for atrial fibrillation (AF) – a serious heart condition that causes an irregular heartbeat.  The Spanish biotech says the latest round – which comes after a $3.8 million first round in […]

  • iRhythm digital heart monitoring service backed by NICE

    A heart monitor developed by iRhythm has become the first product to be endorsed by NICE in a pilot project covering digital health technologies. In new guidance, the health technology assessment (HTA) agency has recommended iRhythm’s Zio XT service for detecting abnormal heart rhythms – provided NHS organisations that deploy it collect evidence of its […]

  • AliveCor Receives FDA Clearance of Next-Gen EKG Algorithms

    What You Should Know: – AliveCor announced they received FDA clearance of new algorithms for use with their personal EKG devices, KardiaMobile and KardiaMobile 6L. These additional determinations will be available via a software upgrade for the Kardia devices in 2021. – The additional FDA-cleared algorithms double the number of heart rhythm disturbances that AliveCor’s […]

  • AI Leads Way to Less False Positives on Remote Cardiac Monitoring Devices, Improved Results

    What You Should Know: – Cardiac patients and their cardiologists are experiencing a high number of false positives with remote patient monitoring devices as a result of signal artifact providing inaccurate data, which can lead to many complications—other than medical, such as unnecessary tests and increased medical costs. – Ambulatory cardiac monitoring provider InfoBionic has […]

  • RHYTHM AI cleared for large trial of atrial fibrillation mapping tool

    UK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, which could be used as a treatment for atrial fibrillation without the need for medication. Antiarrhythmic drugs are standard therapy but they often only work for around 18 months, after which time a catheter ablation procedure is […]

  • AstraZeneca, Eko Collaborate to Advance Innovation Around Heart Failure

    What You Should Know: – Eko today announced a global collaboration with AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart failure.  – Through the collaboration, AstraZeneca and Eko will explore accelerating the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building […]

  • Eko Awarded $2.7M NIH Grant for Heart Murmur & Valvular Heart Disease Detection Algorithms

    What You Should Know: – The National Institutes of Health (NIH) has granted next-generation cardiac AI company Eko an award totaling $2.7 million to support continued collaborative work with Northwestern Medicine Bluhm Cardiovascular Institute – The grant will focus on validating algorithms and help more accurately screen for heart murmurs and valvular heart disease during […]